Skip to main content

Table 1 Characteristics and outcomes of patients who underwent magnetic compression anastomosis for biliary complications after living-donor liver transplantation

From: Magnetic compression anastomosis for the complete dehiscence of hepaticojejunostomy in a patient after living-donor liver transplantation

Years Author No. Age (years) Sex Disease Reconstruction Biliary complication Intervention Distance (mm) Duration from LDLT (months) Period until removal of magnet (days) Duration of internal catheter (weeks) Outcome
2005 Muraoka et al. [15] 1 1 F FH R-Y Stricture CJS N/A 6 12 8 Success
   2 57 M LC R-Y Stricture CJS N/A 7 12 8 Success
2005 Okajima et al. [16] 3 44 F FH D-D Obstruction CCS N/A 12 42 12 Success
2008 Akita et al. [17] 4 34 F N/A D-D Obstruction CCS 5 0 21 0 Success
2008 Mita et al. [18] 5 0.5 F FH R-Y Obstruction CJS N/A 1.5 12 N/A Success
   6 59 F LC R-Y Obstruction CJS N/A 5 25 N/A Success
2009 Matsuno et al. [19] 7 53 M N/A D-D Stricture CCS 3 N/A 10 4.3 Success
2010 Marubashi et al. [13] 8 53 M LC (HBV) D-D Dehiscence CCS N/A 6 63 72 Success
2010 Itoi et al. [20] 9 60 M N/A D-D Obstruction CCS N/A 18 9 24 Success
2011 Kawakubo et al. [6] 10 56 M LC (HCV) R-Y Obstruction CJS N/A 9 23 56 Success
2011 Jang et al. [14] 11 63 F LC (HBV) D-D Stricture CCS N/A 71 42 83 Success
   12 49 M LC (HBV) D-D Stricture CCS N/A 6 26 70 Success
   13 54 M LC (HBV) D-D Stricture CCS N/A 55 18 49 Success
   14 64 F LC (HBV) D-D Stricture CCS N/A 71 71 14 Success
   15 54 M LC (HBV) D-D Stricture CCS N/A 15 102 26.7 Success
   16 48 M LC (HBV) D-D Stricture CCS N/A 13 102 25.7 Success
   17 63 F Liver failure (drug) D-D Stricture CCS 30 107 Failure
   18 33 M Liver failure (HAV) D-D Stricture CCS N/A 5 33 26.7 Success
   19 61 M LC (HBV) D-D Stricture CCS N/A 4 14 25.4 Success
   20 54 M LC (HBV) D-D Stricture CCS N/A 9 181 7.3 Success
   21 52 M LC (HBV) D-D Stricture CCS N/A 1 153 N/A Success
   22 51 M LC (HBV) D-D Stricture CCS N/A 5 Failure
2014 Uemura et al. [21] 23 49 F LC (HCV) D-D Obstruction CCS 11 11 24 13 Success
2016 Ersoz et al. [22] 24 37 M LC (HBV) D-D Dehiscence CCS 15 12 13 N/A Success
   25 54 F LC (HBV, HDV) D-D Dehiscence CCS 10 84 14 N/A Success
   26 53 F LC (HCV) D-D Dehiscence CCS 10 14 42 N/A Success
   27 63 M LC (HBV) D-D Dehiscence CCS 5 7 18 N/A Success
   28 68 F LC (HBV) D-D Dehiscence CCS 10 6 22 N/A Success
   29 54 M LC (HBV) D-D Dehiscence CCS 15 7 13 N/A Success
2017 Saito et al. [23] 30 54 F LC (PSC) R-Y Strangulated ileus CDS 27 60 25 44 Success
2017 Parlak et al. [24] 31 68 F LC (HCV) D-D Obstruction CCS 2.5 14 7 36 Success
   32 52 M LC (HBV) D-D Obstruction CCS 3 22 10 N/A Success
   33 55 M LC (HBV) D-D Obstruction CCS 4 16 2 36 Success
   34 58 M LC (Cryptogenic) D-D Obstruction CCS 6 34 14 48 Success
   35 38 F LC (HBV) D-D Obstruction CCS 3 38 12 48 Success
   36 63 F LC (HCV) D-D Obstruction CCS 3 13 2 44 Success
   37 52 M LC (HBV) D-D Obstruction CCS 4 60 10 N/A Success
   38 54 M LC (HBV) D-D Obstruction CCS 5 15 Failure
   39 62 M LC (Cryptogenic) D-D Obstruction CCS 5 5 Failure
2018 Kubo 40 55 F LC (PSC) R-Y Dehiscence CJS 10 12 21 48 Success
        Dehiscence CJS 10 14 47 76 Success
  Mean   51.6   s     8.9 22.6 35.5 37.6 36/40(90.0%)
  1. FH fulminant hepatitis, LC liver cirrhosis, HAV hepatitis type A virus, HBV hepatitis type B virus, HCV hepatitis type C virus, PSC primary sclerosing cholangitis, D-D duct-to-duct anastomosis, R-Y Roux en Y anastomosis, CCS choledochocholedochostomy, CDS choledochoduodenostomy, CJS choledochojejunostomy, N/A not addressed